Rheumatoid arthritis is associated with systemic inflammation-mediated bone loss, leading to an increased risk of osteoporosis and fractures, particularly in postmenopausal patients. Although disease-modifying antirheumatic drugs may help mitigate bone loss, comparative longitudinal data on different treatment strategies remain limited. This study aimed to evaluate changes in bone mineral density over time and assess the impact of conventional synthetic and biologic DMARDs, together with anti-osteoporotic therapy, on bone health.

Inclusion Criteria:

• Postmenopausal women with a confirmed diagnosis of rheumatoid arthritis

Exclusion Criteria:

• Concomitant inflammatory rheumatic diseases other than RA
• History of malignancy
• Uncontrolled or untreated endocrine or metabolic disorders affecting bone metabolism, such as primary hyperparathyroidism, Cushing's syndrome, severe renal failure, severe hepatic failure
• Incomplete medical records or missing data

This retrospective study was conducted using patient data obtained from the electronic medical records of a university hospital over the past five years.